Vidac Pharma is a clinical-stage biopharmaceutical company advancing first-in-class oncology and onco-dermatology therapies based on a novel approach to cancer metabolism.

The company’s research focuses on targeting abnormal metabolic processes that characterize cancer cells, with the objective of restoring normal cellular regulation and inhibiting tumor progression. Vidac’s scientific platform targets the Warburg effect and forms the foundation of its clinical development programs and pipeline.

Founded in 2012, Vidac Pharma is led by Prof. Max Herzberg and a multidisciplinary leadership team with extensive experience in drug development, life sciences, and corporate management. The company is supported by an international network of scientific and clinical advisors.

Vidac’s lead compound, VDA-1102, is in clinical development for actinic keratosis and cutaneous T-cell lymphoma (CTCL). A next-generation candidate, VDA-1275, is currently in preclinical development, with potential application across a range of solid tumors.

Vidac Pharma maintains a strong intellectual property portfolio and operates within a structured governance and quality framework appropriate for a publicly traded life sciences company.

Vidac Pharma Holding PLC (T9G) is publicly traded on Xetra (Frankfurt Stock Exchange) and the Tradegate Exchange (Germany).
ISIN: GB00BM9XQ619